Description

The study is a global, multicenter, randomized, double-blind, active-controlled, parallel-group study to evaluate the comparative efficacy, safety, immunogenicity, and interchangeability of ADL-018 with US-Xolair® administered subcutaneously (SC) as an add-on therapy for the treatment of adult patients aged 18 to 75 who have been diagnosed with refractory CIU and who remain symptomatic despite standarddosed H1 antihistamine treatment. The study will consist of 4 distinct study periods over a time period of 42 weeks.